Marksans Pharma Limited (BOM: 524404)
India
· Delayed Price · Currency is INR
264.70
+3.25 (1.24%)
At close: Jan 20, 2025
Marksans Pharma Revenue
Marksans Pharma had revenue of 6.42B INR in the quarter ending September 30, 2024, with 20.84% growth. This brings the company's revenue in the last twelve months to 23.79B, up 19.11% year-over-year. In the fiscal year ending March 31, 2024, Marksans Pharma had annual revenue of 21.77B with 17.56% growth.
Revenue (ttm)
23.79B
Revenue Growth
+19.11%
P/S Ratio
n/a
Revenue / Employee
20.85M
Employees
1,141
Market Cap
117.44B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 21.77B | 3.25B | 17.56% |
Mar 31, 2023 | 18.52B | 3.61B | 24.23% |
Mar 31, 2022 | 14.91B | 1.15B | 8.33% |
Mar 31, 2021 | 13.76B | 2.42B | 21.32% |
Mar 31, 2020 | 11.34B | 1.34B | 13.43% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Reliance Industries | 9,398.38B |
Tata Consultancy Services | 2,520.82B |
HDFC Bank | 2,761.06B |
Bharti Airtel | 1,554.78B |
ICICI Bank | 1,638.51B |
Infosys | 1,635.60B |
State Bank of India | 3,360.28B |
ITC Limited | 751.35B |
Marksans Pharma News
- 2 months ago - Marksans Pharma shares jump 2% following USFDA approval for Loratadine Tablets USP 10 mg - Business Upturn
- 2 months ago - Marksans Pharma receives USFDA approval for Loratadine Tablets USP 10 mg - Business Upturn
- 2 months ago - Marksans Pharma Ltd (BOM:524404) Q2 FY25 Earnings Call Highlights: Strong Revenue Growth and ... - GuruFocus
- 2 months ago - Marksans Pharma shares jump over 3% on Q2 results - Business Upturn
- 2 months ago - Marksans Pharma Q2 FY25: Revenue up 20.84% YoY to Rs 641.92 crore, Net Profit up 16.56% YoY - Business Upturn
- 2 months ago - Marksans Pharma Q2 FY25 results: Stock surge over 3% ahead of result announcement - Business Upturn